# Breaking

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/breaking
Canonical HTML page: https://getbiobrief.com/entity/breaking

## Timeline

- **2026-07-20**: Funding talks reported at $20B–$30B valuation — Axios and TechCrunch report Colossal is in discussions to raise new capital at a valuation between $20 billion and $30 billion.
- **2026-06-29**: Tasmanian devil cancer partnership launched — Colossal Foundation partners with University of Tasmania to combat contagious facial cancer in Tasmanian devils.
- **2026-05-15**: Artificial womb tech expected ready in 2027 — CEO Ben Lamm tells Rolling Stone the technology could be spun off for human fertility applications.
- **2026-04-29**: Bluebuck antelope added as sixth target species — Colossal expands de-extinction pipeline to include bluebuck antelope.
- **2026-03-15**: Astromech spinout achieves $2B valuation — AI-driven biology predictive modeling company reaches unicorn status just months after launch.
- **2025-03-15**: Colossal valued at $10.2B after dire wolf project reveal — Investors justify valuation based on broad technology platform, not just de-extinction.

## Recent coverage (1 stories)

### Colossal Biotech Seeks $20B–$30B Valuation on Expanding Gene Platform
2026-07-21 01:00:39 · Sentiment: Very Bullish · Impact: 8/10 · Sources: 2

Colossal Biosciences is reportedly eyeing a valuation of $20 to $30 billion — more than double its 2025 mark — as it transitions from a de-extinction curiosity into a broad gene-editing and AI platform with multiple revenue streams, spinouts in plastics and fertility tech, and growing conservation contracts.
Full story: https://getbiobrief.com/story/colossal-biosciences-20b-30b-valuation-biotech-platform

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.